Mitochondrial genomics in human health and diseases. (How variation in nuclear and mitochondrial DNA causes rare mitochondrial diseases and common late-onset human disorders)

One in every 4,300 people carries a faulty mitochondrial gene that causes severe disability and often early death, with no treatment available. This matters because mitochondria—the tiny power plants inside our cells—have their own DNA, separate from the nuclear DNA we inherit from both parents. When that mitochondrial DNA mutates, the consequences can be devastating: muscle weakness, organ failure, blindness, and neurological damage. The researchers are trying to understand two fundamental puzzles: how these mutations spread through the body's tissues, and how mitochondria talk to the cell nucleus. Without that communication, cells cannot adapt when energy demands change. If this work succeeds, it could lead to the first treatments for mitochondrial diseases—perhaps drugs that boost the cell's ability to cope with faulty mitochondria, or genetic techniques that prevent mutated mitochondrial DNA from being passed to children. The ultimate goal is prevention: stopping these diseases before they start. This is fundamental science with a clear clinical target. The researchers are not promising a cure tomorrow; they are building the molecular understanding needed to design rational therapies. Similar fundamental work on mitochondrial genetics has already enabled mitochondrial replacement therapy, a technique that allows women carrying mitochondrial mutations to have healthy children.